SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharmaceuticals informs about newspaper publication

08 Feb 2023 Evaluate

With reference to its letter No. JPL/CS/1899/2023 dated 7th February, 2023, Jenburkt Pharmaceuticals has informed that it enclosed, clippings of two Newspapers, The Free Press Journal, Mumbai (English) and Navshakti, Mumbai (Marathi) dated 8th February, 2023 containing the standalone Unaudited Financial Results of the Company for the quarter and nine months ended on 31st December, 2022.

The above information is a part of company’s filings submitted to BSE.

Jenburkt Pharma Share Price

1053.45 27.85 (2.72%)
20-Apr-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.30
Dr. Reddys Lab 1234.00
Cipla 1231.50
Zydus Lifesciences 937.50
Lupin 2329.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×